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Abstract
Rationale: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-
year overall survival rate does not exceed 25%.
Patientconcerns:A 55-year-old man affected bymCRC, treated with regorafenib combined with stereotactic body radiotherapy
(SBRT), showing a durable response.
Interventions:After 6 months of regorafenib, a PET/CT scan revealed a focal uptake in a solid lung nodule which was treated with
SBRT, whereas continuing regorafenib administration. Fourteen months later, the patient had further progression in a parasternal
lymph node, but treatment with regorafenib was continued. The regorafenib-associated side effects, such us the hand-foot
syndrome, were favorable managed by reducing the dose from 160 to 120mg/day.
Outcomes: Patient-reported outcome was characterized by a progression-free survival of approximately 3 years.
Lessons: in presence of oligometastatic progression, a local SBRT while retaining the same systemic therapy may be a better
multidisciplinary approach. Moreover, disease progression is no longer an absolute contraindication for continuing the regorafenib
treatment.
Abbreviations: DCR = disease control rate, HFS = hand-foot-syndrome, mCRC = metastatic colorectal cancer, OS = overall
survival, PFS = progression-free survival, SBRT = stereotactic body radiotherapy, SD = stable disease.
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Regorafenib is a novel multikinase inhibitor indicated for
previously treated metastatic colorectal cancer (mCRC) and
currently it is considered a new standard of care in third-line
treatment of mCRC. Treatment with regorafenib has demonstrat-
ed statistically significant improvements in termsofoverall survivalEditor: N/A.
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1(OS), progression-free survival (PFS), and disease control in
comparison to placebo in 2 randomized phase III trials.[1,2] The
CORRECT study showed that the addition of regorafenib to best
supportive care increases OS, compared with best supportive care
only, in mCRC patients who had failed approved standard
therapies.[1] In the CONCUR study, regorafenib resulted in
significantly improved OS, PFS, and disease control rate (DCR)
compared to placebo in Asian patients with refractory mCRC.[2]
The efficacy and safety profiles of regorafenib for mCRChave also
been demonstrated in a large, open-label, single-arm study[3]
(CONSIGN) and in a real-life–based cohort study[4] (REBACCA).
The advent of regorafenib has improved the therapeutic
approach to chemoresistant, late-stage mCRC; nevertheless, the
great majority of patients still have a poor outcome, and the 1-
year OS rate does not exceed 25%. Therefore, in these patients,
an additional locoregional treatment could improve the control
of metastatic disease, even if the optimal strategy for metastatic
progressive disease is still debated.
Stereotactic body radiation therapy (SBRT) delivers large doses
of radiation with great accuracy and it has been successfully used
in both metastatic lung and breast tumors, obtaining a DCR of
approximately 80%.[5,6] However, the clinical experience in the
treatment of mCRC is still scarce.[7]
In this article, we describe the case of an mCRC patient who
had a durable response to regorafenib in association to SBRT,
and thus suggesting a possible new treatment opportunity for
these patients.
Figure 1. Long patient time-line and summary of all treatments carried out from diagnosis. OS = overall survival, PD = progression disease, SBRT = stereotactic
body radiation therapy, SD = stable disease.
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In October 2011, a 55-year-old Caucasian man was diagnosed
with mCRC. He underwent right hemicolectomy with omental
and liver biopsy for a pT3pN0 pM1a (liver), undifferentiated
(G3) mucinous adenocarcinoma of the ascending colon.
Molecular analysis revealed a KRAS codon 12 mutation.
Computed tomography (CT) scan at diagnosis showed multiple
metastases in the right lobe of the liver (V, VI and VII segments,
global diameter 7cm) and multiple, small, with no malignant
characteristics nodules in both lungs. FOLFOX-4 regimen was
started as preoperative strategy for liver metastases resection.
After 6 months of chemotherapy a partial response in the liver
was achieved; therefore, the surgeon suggested a 2-stage right
hepatectomy. However, a re-evaluation by the surgeon in
February 2013 suggested how a right hepatectomy was not
indicated for an inadequate contralateral hypertrophy. There-
fore, a second-line chemotherapy with FOLFIRI plus aflibercept
was started. After 12 cycles of chemotherapy, CT scan showed
stable disease (SD), and aflibercept monotherapy was continued
until severe proteinuria (5000mg/24h) and a blood pressure
increase (150/100mm Hg) occurred, in December 2013.
Considering the long PFS, the patient was referred to a follow-
up program. After 2 months, a 2mm increase of the solid lung
nodule in the superior lingular segment was reported, whereas
liver metastases remained stable. Three months later, a new CT
scan revealed a disease progression in lung (a lingular nodule
change from 7 to 10mm) and the onset of a peritoneal
subdiaphragmatic nodule.
InAugust 2014, a third-line chemotherapywith regorafenibwas
started. After 3 cycles of regorafenib at a standard dosage (160mg
per day for 3 and 1 week rest), a grade 2 hand-foot-syndrome
(HFS) was reported and the dose was reduced to 120mg/day,
leading to an improvement of symptoms. In February 2015, after 6
cycles of regorafenib, a CT scan showed a small size increase
(Dmax 15mm) of a lingular nodule. Our local multidisciplinary
board of gastrointestinal experts suggested to performanSBRT for
lung lesion (54Gydose) and tomaintain regorafenib at a dosage of
120mg/day that was well tolerated. For metabolic evaluation of
persistent disease after SBRT, a PET/CT 18-FDG was performed
and no pathologic uptake areas were identified. The following CT
and PET/CT scan revealed SD until April 2016, when a focal
uptake (SUVmax 4.6) in a right parasternal lymph node was
observed, without any other sites of progression. However, this2oligoprogression in a single lymph node was not considered a
suitable target and therefore the institutional board of gastrointes-
tinal experts decided to treat the mediastinal lymph node with
SBRT and to continue regorafenib treatment.
In July 2016, a PET/CT scan revealed a reduced metabolic
uptake (SUV 1.1) in the lymphadenopathy. Treatment with
regorafenib was maintained and no additional disease progres-
sion was observed. The patient is still undergoing treatment with
regorafenib at a dosage of 120mg/day, with a good tolerability
and a PFS of 36 months (Fig. 1).
3. Discussion
The introduction of novel treatments, mainly consisting of
chemotherapy agents and targeted therapy, has improved the OS
of patients with mCRC.[8] Here, we report the case of a mCRC
patient who had a durable response with regorafenib after the
failure of a first-line treatment with FOLFOX and of a second-
line therapy with FOLFIRI plus aflibercept. The regorafenib-
associated side effects, in particular the HFS, were managed by
reducing the dose from 160 to 120mg/day.
In our view, this case reports the following interesting aspects:
cases of such a long response to regorafenib, with a PFS of 36
months, have been rarely described in mCRC[9]; regorafenib was
maintained despite the appearance of a lung nodule 6 months
after the treatment initiation; SBRT was successfully used in
association with regorafenib as a locoregional treatment. This
novel therapeutic strategy was chosen because the patient had
just a oligometastatic disease.
The term oligometastases, introduced by Hellmann and
Weichselbaum[10] in 1995, describes an intermediate stage of
cancer, between localized and metastatic disease, that is suitable
for local treatment. Niibe and Chang[11] further defined the
concept of oligorecurrence as a disease stage in which there are a
limited number of metastases and in which the primary tumor has
been controlled. In oligometastatic cases, we can use a
multidisciplinary approach aiming to locally control the
metastatic disease (i.e., surgery, radiotherapy, radiofrequency
ablation) while controlling the systemic diseases with concomi-
tant or subsequent oncological therapies (i.e., chemotherapy,
target therapies, and immunotherapies).
In mCRC, surgery is the preferred approach for completely
resectable oligometastases, especially for liver metastases.[12]
Nevertheless, the patient’s comorbidities/age, and the site and
Roberto et al. Medicine (2017) 96:48 www.md-journal.comnumber of metastases could limit the surgical approach and lead
to opt for others local strategies, such as SBRT and radio-
frequency ablation. SBRT is widely used to treat metastases,
because the radiation dose can be precisely delivered to the target
lesion while sparing normal tissue, and therefore is usually well
tolerated; moreover, the duration of the treatment is shorter in
comparison with conventional radiation therapy.[13] SBRT has
been mainly applied to treat nodal metastases, and it has been
also used for solitary lung and liver metastases.[7] However, the
clinical evidence supporting the use of SBRT for treating
oligometastatic disease is still scarce.[7,13,14] Data from these
small clinical studies suggest that liver, lung, isolated lymph
nodes, spinal and adrenal metastasis, and postsurgical pelvic
recurrence can be suitable for SBRT. In unresectable mCRC
metastases, a local treatment with SBRT has shown to be able to
improve patient’s survival and quality of life with low
morbidity.[15]
However, to the best of our knowledge, the combination of
regorafenib and SBRT inmCRC has never been explored yet, and
the present case is the first published case on this subject. A similar
approach (i.e., SBRT delivered during regorafenib treatment to
treat metastases) has been previously described only in 2 patients
affected by metastatic gastrointestinal stromal tumor, achieving
an objective response in the first case and a significant clinical
benefit associated with a local tumor control in the second
case.[16] Also, in our case, we obtained encouraging results, with
an unexpected PFS of 36 months and a good tolerability of the
combined treatment. This good response to regorafenib and
SBRT in a late-stage mCRC suggests that radiotherapy can be
used to treat focally progressing lesions in combination with
systemic therapy, not only with a palliative intent but also to
control the disease. The optimal, multidisciplinary management
of the patient’s disease and adverse events has probably also
contributed to this positive outcome. However, further studies
are needed to confirm the efficacy of SBRT in association to
regorafenib in mCRC oligorecurrence patients.
The patient informed consent was given and the Ethical
approval was not necessary, as it is only a case report.4. Conclusions
This case report shows that regorafenib can improve disease
control and significantly prolongs survival in mCRC, and that the
concomitant use of SBRT is safe and effective. Moreover, it3suggests that disease progression is no longer an absolute
contraindication for continuing the treatment with regorafenib.
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